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Abstract

Introduction

Theoretical considerations as well as clinical
observations suggest that the aggregation of nucleated
crystals is the most dangerous step in the formation of
calcium oxalate (CaOx) renal stones. The effects of 2
major urinary glycoproteins , Tamm-Horsfall glycoprotein (THP) and Nephrocalcin (NC), on calcium oxalate
monohydrate (COM) crystal aggregation in vitro are
studied. At low ionic strength (IS) and high pH (within
urinary limits) , THP is a powerful crystal aggregation
inhibitor (90% inhibition at 40 mg/I) . Decreasing pH to
5.7 and raising IS to 0.21 incr eases THP viscosity,
thereby lowering THP crystal aggregation inhibition .
Upon addition of calc ium (5 mmol / 1), some THPs are no
more soluble and promote crystal aggregation (up to
70 %) . In the presence of citrate (5 mmol/1) , which is
only slightly inhibitory (14 %) , the promoting effect of
THP is reversed into aggregation inhibition (up to 55 %) .
There is evidence for a molecular abnormality in THPs
from severe recurrent CaOx stone formers, since they
exhibit increased polymerization and reduced solubility.
The 14 kD (kilodalton) , Gia-containing glycoprotein NC
also strongly inhib its crystal aggregation . However, NC
isolated from urines of recurrent CaOx stone formers
and from CaOx renal stones are 10 times less inhibitory.
Both are structurally abnormal in that they lack Gia and
are less amphophilic .

Renal stone formation occurs as a consequence of
crystallization within the urinary tract. Crystallization
has two major aspects (19): a thermodynamic one including high urinary supersaturation during which crystal nucleation occurs, and a kinetic one comprising rates
of nucleation , growth and aggregation (agglomeration)
of crystals.
Calcium oxalate crystalluria is a common feature
in recurrent renal stone formers as well as in healthy
people (10, 33). Under identical conditions of dietary
and fluid intake, however , healthy controls excrete only
single calcium oxalate crystals 3-4 µm in diameter,
whereas recurrent calcium stone formers pass large cal cium oxalate crystals (10 - 12 µm diameter), often fused
into polycrystalline aggregates 20-300 µm in diameter
(31). Furthermore, inhibition of the formation of large
calcium oxalate crystal aggregates in vitro by 5 vol% hu man urine is reduced in recurrent calcium stone formers
(32), and renal stones contain highly aggregated crystals
(23). These observations clearly suggest that calcium
oxalate crystal aggregation may be more important for
renal stone formation than crystal nucleation and
growth. This is supported by theoretical considerations:
calcium oxalate crystal growth alone might be too slow
to produce clinically significant particles within renal tubules (9), whereas crystal aggregation occurs within seconds and is, therefore, considered to be much more dangerous for the formation of large crystalline particles
within the urinary tract (4).
There are two main reasons why the urinary compounds that modify calcium oxalate crystal aggregation
are not well defined. First, there is some confusion in
the literature about the definitions of "crystallization"
and "inhibitory activity" (33). In many studies on "crystallization", it is not completely clear whether authors
refer to nucleation, growth or aggregation of crystals.
On the other hand, the term "inhibitor" is being used for
compounds that act as chelators of calcium or oxalate as
well as for molecules binding to the surface of preformed calcium oxalate crystals (33) . Whereas chelators
clearly reduce free ion activity and supersaturation, inhibitors do not influence supersaturation, since they bind

Key Words: nephrolithiasis , calcium oxalate, urinary
inhibitors and promoters, Tamm-Horsfall glycoprotein,
Nephrocalcin.
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to crystal surfaces and block growing sites ("crystal poisoning") at very low (usually micromolar) concentrations
(2) . On the other hand, some molecules act as promoters , probably by providing preformed surfaces for heterogeneous nucleation , epitaxial growth and aggregation
of crystals (2). Because compounds can have varying
effects on different crystallization processes , the term
"modifier" should be used (43), and it should always be
stated whether a speci fie molecule inhibits/promotes
nucleation , growth or aggregation of crystals (33) .
The second reason , why urinary modifiers of calcium oxalate crystal aggregation are poorly understood ,
is the variety of assay systems/conditions
applied for
measuring crystallization processes. In the case of crystal aggregation, measurements usually have been made
under conditions of supersaturation with respect to calcium oxalate, so simultaneous nucleation and growth
might have alter ed crystal aggregation kinetics ( 4 , 7 , 32 ,
36, 39 , 44).
During our own experiments focused on growth of
calcium oxalate monohydrate (COM) crystals in a seeded
system (unpublished) , we observed that spontaneous sedimentation of crystals suspended at equilibrium solution
concentrations was retarded after preincubation with urinary proteins (Fig . 1) . Since average sedimentation velocity of particles falling through a liquid is directly pro portional to average particle size (17), more slowly settling particles must be smaller. In a saturated solution ,
crystals can not nucleate nor grow . Since crystal aggregation also occurs at saturation or even undersaturation
(20) , smaller particles in an equilibrated crystal suspension must be less aggregated .
Table 1 summarizes the basic for ces by which
crystal aggregates in solutions are held together (8): the
attr ac tive van der Waals forces favor particle aggregation, whereas the electrostatic surface potential is repul sive (8 , 20) . The process of viscous binding implies that
crystal foreign molecules are attached to crystal surfaces
and act as a glue between particles , thereby promoting
crystal aggregation (20). If crystalline material connects
several particles (solid bridge formation) , the aggregate
becomes more stable (20) . In a crystal suspension , constant stirring (shear force) basically favors disaggregation (20) ; as expected , slower stirring produces more aggregated particles (4) . Based on these observations, we
have measured COM crystal aggregation in vitro by
spectrophotometrically
monitoring the sedimentation of
crystals that have been pre-aggregated by slow stirring
in an equilibrated suspension (13). It has to be acknowledged, however, that under saturated conditions, macromolecular modifiers possibly might affect COM crystal
aggregation differently from supersaturated conditions
(20). This paper reviews recent work on two major
urinary glycoproteins, Tamm-Horsfall glycoprotein and
Nephrocalcin, with regard to their effects on calcium
oxalate crystallization processes in vitro.

Figure 1. Spontaneous sedimentation of COM crystals.
COM crystal suspensions (0 .8 mg/ml) were incubated
overnight at 37 °C under constant stirring (1 JOOrpm) in
16 x 125 mm glass tubes and then kept standing at room
temperature.
At time zero (upper panel) , there was no
visible difference between control crystals (right) and
crystals pre -incubated with 16 mg/1 of normal human
THP. After 60 minutes (lower panel), particles in the
control suspension had settled almost completely, where as settling was clearly retarded in the presence of THP
(left).
Table 1. Basic forces determining
in stirred suspensions• .

Disaggregating

Aggregating
►
►

►

Van der Waals
Viscous binding
Foreign molecules
"glue"

=

~J

Solid bridges
--1

--v

,

crystal aggregation

►

Electrostatic

repulsion

---..Js

►

11 Zeta potential
Shear force
Turbulence of aqueous
suspensions (stirring)

Stabilization

• Adapted from reference 20 .
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Table 2. THP inhibition of calcium oxalate crystallization

Nucleation
% inhibition

+19

[THP]

~

Growth

-250

+38

50

35

pH

6.5

5.3

IS

0.15

~

Aggregation
~

0

+90

-35

50

8

40

40

6.5

5.7

7.2

5.7

0.15

0.15

0.10

0.21

18

50

13

74

mg/I

Osmol.

1250

mOem/kg

Ref .

18

36

*The most contradicting findings, taken from the literature, are listed . Lower part depicts physico-chemical
at which experiments were performed.
Negative inhibition values = promotion.
IS = ionic strength;
Osmolality;
Ref. = reference .

Tamm-Horsfall Glycoprotein

conditions
Osmol. =

Because THP is present in various amounts in renal stones ( 12), it has been proposed to play a role in renal stone formation . Several studies did not find a difference between normals and calcium oxalate stone formers in the daily urinary excretion of THP, averaging
40-50 mg (3, 12, 38, 47), with the exception of patients
with distal renal tubular acidosis in whom THP excretion
seems to be significantly lower (46). The many in vitro
studies investigating the effects of THP on calcium
oxalate crystal nucleation, growth and aggregation seem
to have revealed very contradicting results.
Table 2
depicts the most conflicting values currently available
from published studies. Kitamura and Pak reported 19 %
inhibition of calcium oxalate crystal nucleation by
normal human THP at 50 mg/1, pH 6.5, 1 mM CaC12
and ionic strength (IS) 0 . 15 (18). At otherwise identical
conditions, but pH 6.0, Yoshioka et al. found promotion
of nucleation by 25% (50). The addition of THP (only
1 mg/1) to synthetic urine in a mixed suspension, mixed
product removal analytic system with very high calcium
(6. 76 mM) and oxalate (l.03 mM) concentrations at pH
5.7 promoted nucleation by 183% (6) . Finally, upon addition of 35 mg THP to 1 liter of extremely concentrated
urine (evaporated to 1250 mOsmole/kg) at pH 5.3, nucleation of amorphous calcium oxalate crystals increased
by 250 % (35) !

The pathophysiology of Tamm-Horsfall glycoprotein (THP), also called uromucoid, has been reviewed
extensively (16, 21, 34). Briefly, THP is produced primarily by the kidneys, where it is specifically localized
to the epithelial cells of the thick ascending limb of
Henle's loop and the most proximal part of the distal tubule (21) . Biochemically, THP is a glycoprotein ; its
carbohydrate content amounts to 30 % . In its monomeric
form, THP isolated from urine by the original salt precipitation method has a molecular weight (MW) of 80
kD (21). The THP gene recently has been cloned and
sequenced; the mature protein contains 616 amino acids.
A very similar protein, uromodulin, has been isolated
from pregnancy urines by lectin adherence; its protein
backbone is identical to THP. During pregnancy, the
protein's carbohydrate structure may be altered; in fact,
uromodulin contains more unprocessed high mannose
chains and is at least 10 times more immunosuppressive
in vitro than salt-precipitated THP (21). The exact function of THP remains enigmatic (16, 21, 34); recent
studies suggest that THP might be a specific ligand for
cytokines in the kidney (21).
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90% aggregation inhibition by normal human THP at 40
mg/I (13) . In a subsequent study, however, lowering pH
to 5. 7 and increasing IS to 0.21 at otherwise unchanged
conditions revealed 35 % promotion of aggregation by 40
mg/1 of THP isolated directly from calcium renal stones
(14).
These apparently paradoxical influences on the
various crystallization processes may be explained by the
well-known physicochemical properties of THP: increasing the concentrations of the protein itse l f (22), divalent cations like calcium and magnesium (5 , 4, 6) , sodium (22, 45) and hydrogen ions (22) all induce increased polymerization (self aggregation) of THP molecules, leading to reversible gel formation (increased viscosity) (11). Scanning electron microscopy studies revealed that THP molecules formed elongated fibers
about 20 nm thick and up to 1000 nm long in solutions
containing NaCl (100 mmol/1) or CaCI 2 (1 mmol/1);
when NaCl plus CaCl 2 were present , however, thick
bundles of fibers, as found in hyaline casts from human
urine, could be seen (48). It is obvious from table 2 that
less THP inhibition or even promotion of calcium oxalate crystallization processes occurred in those studies
performed at lower pH and higher IS .
Studying the effects of increasing IS from 0 .01 to
0.21 at pH 5 .7 on individually purified THPs (40 mg/I)
from normal men and male patients with severe recurrent idiopathic calcium oxalate stone disease ( > 20
stones), we found reduced COM crystal aggregation inhibition in all proteins, but more markedly in stone
former THPs (15) . This was not simply due to lower
solubilities of patient THPs at the experimental conditions (15), but seems to be the consequence of a molecular THP abnormality in patients with severe calcium
oxalate nephrolithiasis:
stone former THP exhibits an
increased tendency to polymerize at lower pH and higher
IS , as evidenced from viscosity measurements and molecular weight determinations (15). Studies on THPs of
the family members of one severe stone former indicate
that this abnormality might be inherited. The molecular
basis of this apparent structural abnormality, however,
remains unknown (15).
Most recently, we studied the effects of high
physiological calcium and citrate concentrations on
COM crystal aggregation inhibition by individual THPs.
After equilibrating COM crystals in 200 mM NaCl and
5 mM CaC12 at pH 5. 70, the rate of crystal aggregation
was identical to the one originally described without additional calcium (13). Urinary THPs of 6 healthy men
and 5 severe male idiopathic calcium stone formers (10200 stones) were studied by adding low amounts of highly concentrated aqueous THP solutions to a final assay
concentration of 40 mg/I. Normal THPs (values mean
± standard error of mean, SEM) inhibited by 13.7 ±
8.8% (range -3.0% to 50.1 %), stone former THPs by 31.4 ± 12.6% (range -68.0 to 7.4%, p < 0.01 versus
normal THPs), e.g . , most stone former proteins actually
promoted crystal aggregation (Fig. 2). Citrate at 5
mmol/1, without any effect on crystal aggregation if no

Inhibition (%) •
(1 - ArHP / Ac> x 100
40

20

%0
-20

-40

-60

~ RCSF

D

Normals

Figure 2. COM crystal aggregation inhibition by normal and stone former THP. COM crystal aggregation
inhibition (%) is measured at pH 5. 7, 200 mM NaCl and
5 mM CaCl 2 . A = crystal aggregation; Ac = aggrega tion in control experiments (no inhibitor added, 0% inhibition); ATHPP= aggregation in the presence of 40 mg/1
of THP from 6 normal men (normals) and 5 recurrent
calcium oxalate renal stone formers (RCSF) . Values are
mean ± SEM . Negative inhibition values = promotion
of crystal aggregation .
Most authors agree that THP is a weak inhibitor
of calcium oxalate crystal growth in vitro . At pH 6 .0 ,
IS 0.15 , 1 mM CaC12 chloride and 0.2 mM sodium oxa late, 50 mg/1 of normal THP inhibited by 3 % (50); at the
same IS, but pH 6.5 and only 0.44 mM calcium and oxalate, respectively , 50 mg/I THP from stone formers inhibited by 38% (18) . In a study performed at pH 5.7, JS
0.15, 1 mM calcium and 0.2 mM oxalate, crystal growth
was not affected by 8 mg/I of THP (49).
Measuring calcium oxalate crystal aggregation
(agglomeration) in vitro in the presence of 5 vol. % human urine before/after removal of THP by antibody precipitation, Felix et al . (7) could not detect an inhibitory
effect of THP . Scurr and Robertson, however, found
22 % aggregation inhibition by 48 mg/I of isolated THP
at pH 6 .0, JS 0.15, 2 mM calcium and 0.4 mM oxalate
(39). Upon addition of oxalate to metastably supersaturated ultra-filtered human urine in the presence of isolated THP (50 mg/I), predominantly small crystals of calcium oxalate monohydrate instead of aggregated calcium
oxalate dihydrate "envelopes" are formed (37) . Using
the newly developed spectrophotometric method at pH
7.2, IS 0.1 and only equilibrium concentrations of calcium and oxalate, e.g ., 0.14 mM each, we found about
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additional calcium was present (13), inhibited by 14.3 ±
3.82% (n=lO). When we restudied the 2 most promoting stone former THPs in the presence of 5 mM citrate,
however, promotion was reversed into inhibition, e.g.,
inhibition changed from -68 % and -45 % (Fig. 2, far left)
to + 55 % and + 34 % , respectively (not shown), clearly
above the slight inhibition by citrate alone. Similar results were obtained with studies in whole urine of our
most severe stone former (200 stones). Crystal aggregation inhibition was measured after incubating unfiltered
fresh 24 hour urine with COM crystals for 36 hours; inhibition was -54 % , e.g., whole urine promoted crystal
aggregation. Since urinary calcium was relatively much
higher than citrate (4.64 versus 1.88 mmol/1), citrate
was added to a final concentration of 6.88 mmol/1; remeasuring crystal aggregation revealed true inhibition of
88%.
Most authors agree that the mechanism, by which
urinary macromolecules inhibit crystal aggregation in
vitro, is their binding to the crystals, which induces a
more negative surface charge (Zeta potential) on the
crystal surface (8, 39). In comparison with glycosaminoglycans and RNA, however, THP produces a less negative Zeta potential on COM crystals (39). Furthermore, two studies have demonstrated that upon raising
THP concentrations within physiologic urinary limits,
e.g., above 10-7 M, Zeta potential does not become any
more negative, e.g., the potential curve flattens off at
about -20 mV (13, 39). Our own studies did not reveal
Zeta potential differences between THPs from healthy
men and severely recurrent stone formers, nor was COM
crystal aggregation inhibition by physiologic THP concentrations correlated to Zeta potential values (15).
We found, however, a negative linear correlation
between crystal aggregation inhibition and intrinsic
viscosity of THP at pH 5. 7 and 200 mM NaCl, e.g.,
THPs with lower viscosities allowed for more crystal aggregation inhibition (14, 15). In accordance with others
(22, 40), our most recent data obtained at pH 5. 7, 200
mM NaCl and 5 mM CaCl 2 suggest an additional role of
THP solubility: measured at room temperature as described elsewhere (15), THP solubility (mean ± SEM)
was 61.0 mg/I for normal and 34.8 mg/I for stone former THP (p < 0.01). When adding 40 mg of dry stone
former THP to 1 liter buffer solution (pH 5. 7, NaCl 200
mM, CaCl 2 5 mM), visible hair-like precipitates were
regularly detectable .
Altogether, there is strong evidence for a dual
role of THP in COM crystal aggregation. At higher pH
and lower IS, THP is a powerful aggregation inhibitor.
Upon lowering pH and raising IS within physiologic urinary limits, increased polymerization of THP molecules
occurs. This most possibly increases attractive viscous
binding forces on COM crystal surfaces. Since the repulsive Zeta potential is not increased any further, the
overall forces between crystals become more attractive,
allowing for more crystal aggregation (reduced inhibition). If in addition high physiological calcium concentrations are present, certain THPs even may form

glycoprotein

& Nephrocalcin

insoluble precipitates on which crystals preferably
aggregate (promotion of aggregation). This seems to be
reversed by equimolar concentrations of citrate, suggesting a higher affinity of calcium ions to citrate than to
THP. As our recent data indicate, some stone former
THPs have an increased tendency of polymerization and
lower solubilities than normal THPs. These findings,
however, do not exclude that, in a given clinical
situation, an extreme difference in the chemical composition of urine between stone formers and normals might
in itself produce various THP effects irrespective of
molecular THP abnormalities.

Nephrocalcin
In 1978, Nakagawa et al. (24) isolated an acidic
glycoprotein from human urine which strongly inhibited
the growth of COM crystals in vitro. Subsequently, the
same glycoprotein was also purified from human kidney
tissue culture medium (25). Since further characterization demonstrated that the protein contained gammacarboxyglutamic acid (Gia) (26), it later was named
nephrocalcin (NC), in analogy with osteocalcin, the Giacontaining bone protein (28). In its monomeric form,
NC has a molecular weight of 14 kD; it contains calcium
and magnesium ions that are likely to be involved in the
formation of aggregates of higher molecular weights in
human urine (26). NC is rich in acidic amino acids and
contains 10 weight% of carbohydrates (26); it does not
contain any uronic acids (30). The glycoprotein shows
a strong surface activity as evidenced by a very high
collapse pressure at air-water interfaces, suggesting
strong amphophilic properties and a highly organized
two-dimensional structure of NC (26).
There are several lines of evidence for a renal origin of NC. To date, NC has been isolated from kidney
tissue of nine vertebrae species (30). Primary cultures
of mouse proximal tubule cells produce NC (42). Renal
cell cancers, which are believed to originate from proximal tubule cells, seem to produce NC as well, as evidenced from the purification of NC from the culture
medium of renal carcinoma cells (41). Immunohistochemically, NC could be localized to the proximal tubule
and the thick ascending limb of Henle' sloop in mouse as
well as in human kidneys; there was no cross-reactivity
with THP (29). Daily urinary excretion of NC in humans amounts to about 20 mg; there seems to be no difference between normals and renal stone formers (M.
Netzer, personal communication).
NC isolated from normal human urine is a strong
inhibitor of COM crystallization processes in vitro.
Using a constant composition assay, Asplin et al. recently demonstrated that NC (as well as 20 % dialyzed human urine) inhibited the secondary nucleation of calcium
oxalate on COM crystals as well as crystal growth (1).
By means of a seeded crystal growth system, NC purified from normal human urines and from human kidney
tissue culture medium repeatedly has been shown to
strongly inhibit COM crystal growth at concentrations
between 10-9 and 10-6 M (25-28, 49). Our own studies
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demonstrated that normal NC at concentrations between
5 x 10-8 and 1 x 10-6 M also is a powerful inhibitor of
COM crystal aggregation (13). Opposite to THP, increasing ionic strength or lowering pH of the solution
did not affect the inhibitory activity of normal NC at
physiologic concentrations (13).
Considering the mechanism of NC inhibition, it
is important to note that patients with recurrent calcium
oxalate nephrolithiasis produce a structurally defective
NC (27); NC with the same abnormalities has also been
isolated from human calcium oxalate renal stones (28).
Both stone former and stone NC lack gamma-carboxyglutamic acid, are less amphophilic (formation of less
stable air-water interfacial films) and induce a less negative Zeta potential on COM crystal surfaces (I 3, 27,
28). Functionally, stone former as well as stone NC are
weak crystal aggregation inhibitors at physiologic concentrations (about 10-fold less effective than normal
NC); however, increasing their concentrations above the
physiologic range raises inhibitory activity to normal
levels (13). Since progressively increasing the concentrations of these defective NCs improves their inhibitory
activity yet does not alter crystal surface charge (13), we
conclude that their weaker amphophilic properties,
possibly due to the lack of gammacarboxyglutamic acid,
may be responsible for the loss of COM crystal aggregation inhibition . One might speculate that conformational
changes in the defective forms of NC, when bound to
COM crystals, allow for relatively more viscous binding
on the crystal surface. However, promotion of crystal
aggregation, as found in abnormal THP, has never been
demonstrated for defective NC.
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Discussion with Reviewers

binding of COM crystals . If this is true, does the
production of Jess negative charge on COM crystal
surface really matter?
Author: As mentioned above, it is purely speculative to
state that defective forms of NC might allow for more
viscous binding on COM crystal surfaces. This was done
in analogy to THP, where increasing concentrations
within the physiologic range also do not raise the negative Zeta potential yet inhibitory activity changes (see
also my answer to first question by Prof. Robertson).
Therefore , I agree, that the negative Zeta potential does
not seem to contribute really to the differences in COM
crystal aggregation inhibition that we observe, at least
not under our experimental conditions and at the (physiologic) concentrations of both THP and NC we have
chosen for our studies.

W.G. Robertson: Why under certain conditions does
THP appear to exert an inhibitory effect on agglomeration yet, according to the author, does not show any relationship with Zeta potential?
Author: The extent of crystal aggregation (agglomeration) in vitro is determined by attractive and repulsive
forces that are balanced against each other (Table 1).
As demonstrated by your group (40) and our own results
(13), increasing THP concentration within physiologic
limits does not change Zeta potentials. Therefore, given
constant stirring rates in our system, the overall repulsive force remains constant, and increased THP inhibition (less crystal aggregation) must be the consequence
of reduced attractive forces. We find that THPs with
low viscosities, e.g., less polymerized molecules, inhibit
crystal aggregation more markedly than THPs with high
viscosities (14, 15). One explanation would be that low
viscosity THP molecules, compared to more viscous
THP polymers, produce less viscous binding, which
would lead to a relative increase of net particle repulsion, e.g., more crystal aggregation inhibition.

D.J. Kok: Is there a correction applied for the difference in density between single crystals and their aggregates?
Author: I am aware of the fact that the density of crystals and their aggregates does not have to be identical;
however, no such correction was applied in our in vitro
system.

W.G. Robertson: Is there any relationship between the
structure of NC and that of part of the THP molecule as
was suggested by one group?
Author:
I cannot answer this question, since the
primary structure of NC is still under investigation.

D.J. Kok: It has been shown before that the effect of
citrate on crystal agglomeration depends on the type of
complexes formed in solution. It can be increased by
the presence of magnesium or by changing the calcium
concentration. What evidence does the author have that
this is not the case here?
Author: Magnesium was never present in our assay solutions. We can , however, demonstrate an increased inhibitory effect of citrate upon formation of calcium citrate complexes. Previously, when calcium was present only at equilibrium concentration (0.14 mM) in our
system (13), we had not found any effect of millimolar
citrate concentrations on COM crystal aggregation. The
experiments presented in this paper were performed with
5 mM calcium and, therefore, allowed for calcium-citrate complex formation; in fact, we demonstrate 14.3%
inhibition by 5 mM citrate. Our most recent studies (unpublished) indicate a 45 % increase of aggregation inhibition by normal THPs after addition of citrate, considerably more than with citrate alone . This additional increase must be related to THP itself, possibly because
calcium is mainly chelated by citrate and can no longer
induce conformational changes of THP molecules (polymerization) to the same extent.

S.R. Khan: What happens to the calcium oxalate zeta
potential in the presence of NC?
Author : As demonstrated by our own studies ( 13), NC
also induces a negative Zeta potential on COM crystals.
Similar to THP, increasing NC concentrations within
physiologic urinary limits does not raise any further the
negative Zeta potential, e.g., the potential curve flattens
off at about -18 mV. Defective NCs, isolated either
from stone former urines or directly from CaOx renal
stones, induce a less negative Zeta potential of about -13
mV on COM crystal surfaces (13).
M. Akbarieh and R. Tawashi: Increasing THP concen tration, increasing the IS and changing pH could lead to
increased aggregation (polymerization!) of the protein.
What critical precaution the author suggests in the preparation and purification that could minimize the effect of
these variables?
Author: We routinely purify THP from human urines
by the classical method of repeated salt precipitation,
modified, however, by using 4 M urea in 0.02 M sodium
phosphate, pH 6.8, and gel filtration (Sepharose 4B) as
a final purification step (13). This minimizes the effect
of pH and IS; in addition, increasing the urea concentration is known to decrease THP viscosity (16, 21).

D.J. Kok: The structural changes in THP and NC may
represent two different groups of calcium oxalate stone
formers or there may be some (cellular?) aberrance connecting both. Does the author have any information
supporting one of these hypotheses?
Author: I do not have any information on either of the
two hypotheses.

N. Akbarieh and R. Tawashi: The author speculates
that the structurally defective forms of NC present in
stone former urines and renal stones lead to viscous
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